scholarly journals Proteome alterations associated with transformation of multiple myeloma to secondary plasma cell leukemia

Oncotarget ◽  
2016 ◽  
Vol 8 (12) ◽  
pp. 19427-19442 ◽  
Author(s):  
Alexey Zatula ◽  
Aida Dikic ◽  
Celine Mulder ◽  
Animesh Sharma ◽  
Cathrine B. Vågbø ◽  
...  
Keyword(s):  
Multiple Myeloma ◽  
Plasma Cell ◽  
Plasma Cell Leukemia ◽  
Cell Leukemia ◽  
Secondary Plasma

Clonal evolution at leukemic relapse of multiple myeloma (secondary plasma cell leukemia) responding to re-treatment with bortezomib-based therapy. A case record

2010 ◽  
Vol 34 (4) ◽  
pp. e104-e105 ◽  
Author(s):  
Paolo Bernardeschi ◽  
Maria Teresa Pirrotta ◽  
Iolanda Montenora ◽  
Gloria Giustarini ◽  
Maria Immacolata Ferreri ◽  
...  
Keyword(s):  
Multiple Myeloma ◽  
Plasma Cell ◽  
Clonal Evolution ◽  
Plasma Cell Leukemia ◽  
Cell Leukemia ◽  
Case Record ◽  
Leukemic Relapse ◽  
Secondary Plasma

scholarly journals Secondary Plasma Cell Leukemia in a Recurrent Multiple Myeloma: Rare Case Scenario

Cureus ◽  
2020 ◽  
Author(s):  
Arati A Inamdar ◽  
Abraham Loo ◽  
Nagy Mikhail ◽  
Patrick Lee
Keyword(s):  
Multiple Myeloma ◽  
Plasma Cell ◽  
Rare Case ◽  
Plasma Cell Leukemia ◽  
Cell Leukemia ◽  
Case Scenario ◽  
Secondary Plasma

scholarly journals A Case of Rare Subtype of Multiple Myeloma: Secondary Plasma Cell Leukemia

2021 ◽  
Vol 2 (1) ◽  
Author(s):  
Chandra Sanwal ◽  
Aftab Mahmood ◽  
Michael Bailey ◽  
Krutika Patel ◽  
Antonio Guzman
Keyword(s):  
Multiple Myeloma ◽  
Plasma Cell ◽  
Plasma Cell Leukemia ◽  
Cell Leukemia ◽  
Secondary Plasma

scholarly journals Secondary plasma cell leukemia in a patient with light chain multiple myeloma in post-chemotherapy remission phase

2014 ◽  
Vol 5 (3) ◽  
pp. 111
Author(s):  
DaniaLizet Quintanilla-Flores ◽  
René Rodríguez-Gutiérrez ◽  
MiguelÁngel Flores-Caballero
Keyword(s):  
Multiple Myeloma ◽  
Plasma Cell ◽  
Light Chain ◽  
Plasma Cell Leukemia ◽  
Cell Leukemia ◽  
Remission Phase ◽  
Secondary Plasma

scholarly journals Pixantrone demonstrates significant in vitro activity against multiple myeloma and plasma cell leukemia

2019 ◽  
Vol 98 (11) ◽  
pp. 2569-2578
Author(s):  
Ella Willenbacher ◽  
Karin Jöhrer ◽  
Wolfgang Willenbacher ◽  
Brigitte Flögel ◽  
Richard Greil ◽  
...  
Keyword(s):  
Multiple Myeloma ◽  
Cell Lines ◽  
Plasma Cell ◽  
Myeloma Cell ◽  
Plasma Cell Leukemia ◽  
Phase Iii ◽  
In Vivo Model ◽  
Cell Leukemia ◽  
Cam Assay

Abstract Treatment results for multiple myeloma and plasma cell leukemia have considerably improved, but cure remains elusive and establishing new therapeutic approaches constitutes a major unmet clinical need. We analyzed the anti-myeloma properties of the aza-anthracenedione pixantrone which has been successfully used in a phase III study for the treatment of patients with aggressive non-Hodgkin’s lymphoma as monotherapy as well as in combination regimes in vitro and in an adapted in vivo model (ex ovo chicken chorioallantoic membrane (CAM) assay). Pixantrone significantly inhibited proliferation and metabolic activity of all investigated myeloma cell lines. Importantly, anti-myeloma effects were more pronounced in tumor cell lines than in stromal cells, mesenchymal stem cells, and peripheral blood mononuclear cells of healthy controls. Apoptosis of myeloma cell lines was observed only after a 7-day incubation period, indicating a fast cytostatic and a slower cytotoxic effect of this drug. Pixantrone reduced the viability of primary plasma cells of patients and induced downregulation of myeloma-cell growth in the CAM assay. Additionally, we demonstrate in vitro synergism between pixantrone and the histone deacetylase inhibitor panobinostat with respect to its anti-proliferative features. From these data, we conclude that systematic investigations of the clinical usefulness of pixantrone in the framework of controlled clinical trials are clearly indicated (e.g., in penta-refractory patients).

Treatment with bortezomib-based regimens improves overall response and predicts for survival in patients with primary or secondary plasma cell leukemia: Analysis of the Greek myeloma study group

2013 ◽  
Vol 89 (2) ◽  
pp. 145-150 ◽  
Author(s):  
Eirini Katodritou ◽  
Evangelos Terpos ◽  
Charikleia Kelaidi ◽  
Maria Kotsopoulou ◽  
Sossana Delimpasi ◽  
...  
Keyword(s):  
Plasma Cell ◽  
Plasma Cell Leukemia ◽  
Study Group ◽  
Cell Leukemia ◽  
Overall Response ◽  
Secondary Plasma

Lack ofBCL10 mutations in multiple myeloma and plasma cell leukemia

2001 ◽  
Vol 30 (4) ◽  
pp. 402-406 ◽  
Author(s):  
Lee-Yung Shih ◽  
Jen-Fen Fu ◽  
Sheila A. Shurtleff ◽  
Stephan W. Morris ◽  
James R. Downing
Keyword(s):  
Multiple Myeloma ◽  
Plasma Cell ◽  
Plasma Cell Leukemia ◽  
Cell Leukemia

Discordant LFA-1/ICAM-1 expression in a case of secondary plasma cell leukemia associated with subcutaneous plasmacytoma

1993 ◽  
Vol 42 (3) ◽  
pp. 299-304 ◽  
Author(s):  
Hiroshi Tsutani ◽  
Taeko Sugiyama ◽  
Shiro Shimizu ◽  
Hiromichi Iwasaki ◽  
Takanori Ueda ◽  
...  
Keyword(s):  
Plasma Cell ◽  
Plasma Cell Leukemia ◽  
Cell Leukemia ◽  
Secondary Plasma
Sign in / Sign up

Export Citation Format

Share Document